These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 35708849)

  • 1. Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors.
    Park BC; Jung S; Chen ST; Dewan AK; Johnson DB
    Am J Clin Dermatol; 2022 Sep; 23(5):707-717. PubMed ID: 35708849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitor-related dermatologic adverse events.
    Geisler AN; Phillips GS; Barrios DM; Wu J; Leung DYM; Moy AP; Kern JA; Lacouture ME
    J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
    Bhardwaj M; Chiu MN; Pilkhwal Sah S
    Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic accuracy of general dermatologists and supportive oncodermatologists for biopsied cutaneous immune-related adverse events.
    Thompson LL; Said JT; Li EB; Yoon J; Krasnow NA; Molina GE; Polyakov NJ; Foreman RK; LeBoeuf NR; Chen ST
    Support Care Cancer; 2022 Oct; 30(10):7827-7831. PubMed ID: 35804176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of immune checkpoint inhibitor-related dermatologic adverse events.
    Si X; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Wang M; Zhang L
    Thorac Cancer; 2020 Feb; 11(2):488-492. PubMed ID: 31814310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy.
    Haanen J; Ernstoff M; Wang Y; Menzies A; Puzanov I; Grivas P; Larkin J; Peters S; Thompson J; Obeid M
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32532839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
    Chen CH; Yu HS; Yu S
    Curr Oncol; 2022 Apr; 29(4):2871-2886. PubMed ID: 35448208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy.
    Keiser MF; Patel AB; Altan M
    Clin Lung Cancer; 2021 May; 22(3):195-200.e1. PubMed ID: 33637416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous immune-related adverse events to checkpoint inhibitors.
    Malviya N; Tattersall IW; Leventhal J; Alloo A
    Clin Dermatol; 2020; 38(6):660-678. PubMed ID: 33341200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement.
    Apalla Z; Nikolaou V; Fattore D; Fabbrocini G; Freites-Martinez A; Sollena P; Lacouture M; Kraehenbuehl L; Stratigos A; Peris K; Lazaridou E; Richert B; Vigarios E; Riganti J; Baroudjian B; Filoni A; Dodiuk-Gad R; Lebbé C; Sibaud V
    J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):332-350. PubMed ID: 34910332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review.
    Apalla Z; Papageorgiou C; Lallas A; Delli F; Fotiadou C; Kemanetzi C; Lazaridou E
    Dermatol Pract Concept; 2021 Jan; 11(1):e2021155. PubMed ID: 33614223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical Presentations and Management of Endocrine and Hepatic Immune-Related Adverse Events From Adjuvant Immune Checkpoint Inhibitor Therapy in Stage III Resected Melanoma.
    Kottschade LA; Yan Y
    JCO Oncol Pract; 2020 Feb; 16(2_suppl):10s-14s. PubMed ID: 32045536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous adverse events caused by immune checkpoint inhibitors.
    Quach HT; Johnson DB; LeBoeuf NR; Zwerner JP; Dewan AK
    J Am Acad Dermatol; 2021 Oct; 85(4):956-966. PubMed ID: 34332798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatologic toxicities of targeted antineoplastic agents and immune checkpoint inhibitor therapy in pediatric patients: A systematic review.
    Liu LY; Teng JMC; Spunt SL; Strelo JL; Kwong BY; Zaba LC
    Pediatr Blood Cancer; 2021 Dec; 68(12):e29346. PubMed ID: 34569142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating patterns of co-occurrence between cutaneous and noncutaneous immune-related adverse events after immune checkpoint inhibitor therapy.
    Asdourian MS; Shah N; Jacoby TV; Thompson LL; Otto T; Semenov YR; Reynolds KL; Chen ST
    J Am Acad Dermatol; 2023 Jan; 88(1):246-249. PubMed ID: 35577231
    [No Abstract]   [Full Text] [Related]  

  • 18. Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.
    Gnanendran SS; Turner LM; Miller JA; Hwang SJE; Miller AC
    Curr Treat Options Oncol; 2020 Mar; 21(4):29. PubMed ID: 32193712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies.
    Ransohoff JD; Kwong BY
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):834-851. PubMed ID: 28918995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
    Nagai H; Muto M
    Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.